Chronic Lymphocytic Leukaemia clinical trials

Explore recruiting chronic lymphocytic leukaemia clinical trials.

Recruiting chronic lymphocytic leukaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Lymphocytic Leukaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicentre, Open-Label, Randomized, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) with Chronic Lymphocytic Leukemia and Moderate to Severe Cardiac Impairment

Spain, Italy, Poland, Czechia

Therapeutic use (Phase IV) EU CTIS Study details

Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC)

Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Romania, Poland, Hungary, Bulgaria, Croatia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in patients with relapsed/refractory CLL - (CLL2-BZAG)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Lymphocytic Leukaemia trials by city

Chronic Lymphocytic Leukaemia in Toronto Chronic Lymphocytic Leukaemia in Vancouver Chronic Lymphocytic Leukaemia in Montreal Chronic Lymphocytic Leukaemia in Calgary Chronic Lymphocytic Leukaemia in Edmonton Chronic Lymphocytic Leukaemia in Ottawa Chronic Lymphocytic Leukaemia in Winnipeg Chronic Lymphocytic Leukaemia in Quebec City Chronic Lymphocytic Leukaemia in Hamilton Chronic Lymphocytic Leukaemia in Kitchener Chronic Lymphocytic Leukaemia in London Chronic Lymphocytic Leukaemia in Halifax Chronic Lymphocytic Leukaemia in New York Chronic Lymphocytic Leukaemia in Los Angeles Chronic Lymphocytic Leukaemia in Chicago Chronic Lymphocytic Leukaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease